Incretin mimetics are a new class of pharmacological agents with multiple antihyperglycemic actions that mimic several of the actions of incretin hormones originating in the gut, such as glucagon-like peptide (GLP)-1. Dipeptidyl peptidase-IV (DPP-IV) inhibitors suppress the degradation of many peptides, including GLP-1, thereby extending their bioactivity. These agents seem to have multiple mechanisms of action for the treatment of type 2 diabetes mellitus (T2DM), including some or all the following: enhancement of glucose-dependent insulin secretion, suppression of inappropriately elevated glucagon secretion, slowing of gastric emptying, and decreased food intake. Exenatide (BYETTA®) is the first incretin mimetic approved for clinical use by the US Food and Drug Administration. In phase 3 clinical trials, exenatide reduced HbA1c by ~1% and body weight by ~2 kg in T2DM patients failing to achieve glycemic control with metformin and/or a sulfonylurea, with mild-to-moderate nausea the most common side effect. Several GLP-1 analogues and DPP-IV inhibitors are in late-stage clinical testing and may soon become available for treating T2DM patients. The use of these agents may provide an opportunity to bring about new improvements in diabetes care. (J Am Board Fam Med 2006;19:612–20.)

Type 2 diabetes mellitus (T2DM) is characterized by the emergence of postprandial (post-meal) and subsequently, fasting hyperglycemia (fasting plasma glucose concentrations >125 mg/dL).1,2 Hyperglycemia results from a failure of pancreatic β-cells to secrete adequate insulin to compensate for insulin resistance in peripheral tissues.3,4 The increasing worldwide prevalence of T2DM (American Diabetes Association. 2006. [monograph on the Internet]. Total prevalence of diabetes and prediabetes. Available from: http://www.diabetes.org/diabetes-statistics/prevalence.jsp) has major implications for both health care systems and affected individuals, particularly because of the vascular complications associated with this disease. The aim of pharmacological therapy for T2DM (Table 1) is to control hyperglycemia and, ultimately, to avert the serious complications associated with sustained tissue exposure to excessively high glucose concentrations. However, due to the complex nature of the disease and the progressive deterioration in pancreatic β-cell function, glycemic control remains difficult. Despite the use of intensive therapy, the United Kingdom Prospective Diabetes Study (UKPDS) found that glycemic control continued to deteriorate over time,5 and despite currently available therapies, the majority of T2DM patients in the United States continue to have poor diabetes control, as reflected by glycohemoglobin A1C (HbA1c) concentrations greater than 7% in more than 60% of T2DM patients.6–8

The most widely used combination of oral therapy for T2DM patients is metformin with a sulfonylurea.7,9–11 Both drugs can be safe and effective when used either as monotherapy or in combination, albeit with a risk of drug-associated side effects.7,9–11 The question of which therapies are best when this combination no longer produces acceptable glycemic control is a topic of significant debate. Addition of insulin or a thiazolidinedione are popular options, but each agent is associated with additional side effects, including weight gain, in a patient population that is generally overweight or obese.9,12–14 The reasons for weight gain in T2DM are many, and include compensatory eating to avoid hypoglycemia, decreased glucosuria, and de-
Increased basal metabolic rate, as well as changes in adipose tissue and fluid retention.15–17 For T2DM patients, excess weight can increase the risk of mortality; up to 8-fold for those with weight >40% above ideal target weight.14 In contrast, weight loss can positively impact T2DM, with improvements
in fasting hyperglycemia reported as early as the first week of weight loss, and accompanying reductions in HbA1c noted with sustained weight loss. It has been reported that an average weight loss of 5% has been associated with an 0.6% reduction in HbA1c. Weight loss also improves the cardiovascular risk factors of dyslipidemia and hypertension and decreases the need for glucose-lowering agents.

New T2DM treatments may be needed to address the growing disease burden. This review will discuss 2 new classes of antidiabetic agents, incretin mimetics and dipeptidyl peptidase-IV (DPP-IV) inhibitors. Exenatide (BYETTA®, Amylin Pharmaceuticals Inc., San Diego CA and Eli Lilly and Company, Indianapolis, IN) is the first incretin mimic approved for clinical use by the FDA. In addition, a number of other agents in both drug classes are undergoing late-stage clinical testing (liraglutide, vildagliptin, sitagliptin, saxagliptin). Through different mechanisms, these agents elicit glucoregulatory actions similar to those of the mammalian incretin hormone glucagon-like peptide (GLP)-1.

**Incretins**

The role of intestinal peptides in the regulation of postprandial insulin secretion was first identified by the observation that insulin secretion from pancreatic β-cells was more robust after an oral glucose bolus than after an equivalent, intravenous glucose bolus. This “incretin effect” was attributed to the insulinotropic action of gut hormones, specifically GLP-1 and glucose-dependent insulinoportal polypeptide (GIP). T2DM patients generally lack the glucose-lowering response to GIP. In contrast, the insulinotropic response to GLP-1 is intact, but circulating levels of postprandial GLP-1 are deficient. Therefore, therapeutic interventions have focused on exerting a pharmacological GLP-1 effect.

The biological activities of GLP-1 include (1) glucose-dependent insulin secretion to aid tissue uptake of plasma glucose, (2) suppression of postprandial glucagon to reduce hepatic glucose release, (3) slowing of gastric emptying to avoid overwhelming the circulation with glucose as food is absorbed from the gut, and (4) suppression of food intake (appetite). In addition, animal data suggest that GLP-1 regulates maintenance of pancreatic β-cell mass as a normal physiologic function.

In mammals, GLP-1 is secreted by mucosal L-cells of the small intestine and the insulinoportal activity of GLP-1 is mediated through GLP-1 receptors on pancreatic β-cells. The release of GLP-1 in response to a meal occurs rapidly (within 10 minutes) in healthy individuals and is highly correlated with insulin secretion into the circulatory system. In T2DM patients, or individuals with impaired glucose tolerance (pre-diabetes), this response is defective, resulting in reduced circulating concentrations of postprandial GLP-1 which contributes to a blunted insulin secretory response to meals.

The ability of GLP-1 to control glucose excursions in preclinical diabetes models led to a series of GLP-1 clinical trials in humans. Continuous infusion of GLP-1 into T2DM patients nearly normalized glycemia. The insulinotropic and glucagonostatic actions of GLP-1 were shown to be glucose dependent; in other words, as the action of GLP-1 subsided, euglycemia was restored. The rapid degradation of GLP-1 (half-life less than 2 minutes) by the enzyme DPP-IV limited the feasibility of GLP-1 as a potential therapeutic.

**Incretin Mimetics**

Incretin mimetics are a new class of pharmacological agents with multiple antihyperglycemic actions that mimic some effects of endogenous incretin hormones, including glucose-dependent enhancement of insulin secretion. Although these agents may exhibit glucoregulatory effects similar to those of GLP-1, their actions might not be mediated solely through the pancreatic GLP-1 receptor. Therefore, the class name “incretin mimetic” is intended to emphasize the glucoregulatory and metabolic effects of these agents, rather than their specific mechanisms of action.

Several incretin mimetic GLP-1 analogues have been developed that are resistant to degradation by DPP-IV. Liraglutide (Novo Nordisk, Copenhagen, Denmark) and CJC-1131 (Conjuchem, Montreal, Canada) have undergone the most extensive testing to date of the GLP-1 analogues. Liraglutide is in phase 2 clinical trials. However, further clinical development of CJC-1131 has been put on hold in favor of CJC-1134, an exendin-4 conjugate, according to 30 September 2005 and 25 January 2006 press releases from Conjuchem and, therefore, will not be discussed further. Exenatide, which is not a
GLP-1 analogue, is the first incretin mimetic approved for clinical use by the FDA.

**Liraglutide**

Liraglutide is a GLP-1 analogue. In early clinical trials, liraglutide displayed multiple glucoregulatory activities similar to the actions of endogenous GLP-1. Liraglutide suppressed postprandial glucose excursions, reduced fasting plasma glucose concentrations, enhanced first-phase insulin response after meals, and suppressed postprandial plasma glucagon concentrations. In one phase 2 study, liraglutide treatment was associated with reduced HbA1c (−0.8%) compared with placebo. Nausea and other gastrointestinal adverse events were the most frequent side effects reported.

**Exenatide**

Exendin-4, the naturally occurring form of exenatide, was originally isolated from the salivary secretions of the lizard Heloderma suspectum (Gila monster). In the Gila monster, exendin-4 circulates after the lizard bites down on its prey (ingestion of a meal) and thus represents the first example of an endocrine hormone secreted from salivary glands. Exendin-4 is resistant to degradation by mammalian DPP-IV and, thus, has a much longer plasma half-life than GLP-1.

Exenatide and GLP-1 share certain glucoregulatory activities, including glucose-dependent enhancement of insulin secretion, glucose-dependent suppression of inappropriately high glucagon secretion, slowing of gastric emptying, and reduction of food intake. In addition, exenatide has been shown to restore first-phase insulin secretion and to promote β-cell proliferation and islet neogenesis from precursor cells in both in vitro and in vivo models of diabetes.

The results of 3 double-blinded, placebo-controlled exenatide phase 3 clinical trials in T2DM patients treated with metformin, an antidiabetic sulfonylurea, or both, have been reported. Thirty weeks of exenatide dosing (5 μg or 10 μg subcutaneously, twice daily) significantly reduced HbA1c, fasting plasma glucose, and postprandial glucose excursions. Mean HbA1c reductions from baseline in the 10 μg exenatide groups ranged from −0.9% to −0.8% compared with +0.1% to +0.2% in the placebo groups. In addition, progressive reductions in body weight were observed, with means ranging from −2.8 kg to −1.6 kg in the 10 μg dosing groups by week 30, compared with −0.9 kg to −0.3 kg in the placebo group (P < .05). In an interim assessment of ongoing, open-label extensions of these trials, patients with 82 weeks of 10-μg exenatide exposure had sustained HbA1c reductions from baseline of −1.1 ± 0.1%, with 48% of patients achieving HbA1c ≤7%, suggesting durability of glycemic control in this group. This same patient cohort had progressive weight reductions from baseline of −4.4 ± 0.3 kg, supporting the continuing nature of the weight loss in this group. Exenatide was generally well tolerated. Mild-to-moderate nausea was the most common adverse event related to exenatide exposure, and the incidence of nausea decreased with continued treatment. Mild hypoglycemia was most commonly observed in patients also treated with a sulfonylurea.

A subsequent clinical trial was designed to determine whether exenatide could be used as an alternative to insulin glargine. In this 26-week, randomized, open-label study, the non-inferiority of exenatide to insulin glargine was demonstrated in T2DM patients who were generally middle-aged, overweight (mean BMI of 31 kg/m²), and had suboptimal glycemic control with advanced disease duration. At week 26, HbA1c was reduced from baseline by equivalent degrees in both treatment arms (mean −1.1%). In contrast, body weight decreased in exenatide-treated patients (mean −2.3 kg), but increased in insulin-treated patients (mean ± 1.8 kg). The most common adverse event among exenatide-treated patients was mild-to-moderate nausea that decreased in incidence over time. The overall rate of hypoglycemia was not different across treatment arms; however, exenatide patients experienced a lower incidence of nocturnal hypoglycemia coupled with a higher incidence of daytime hypoglycemia compared with insulin glargine.

Pharmacological studies indicate that exenatide dosing is not recommended during the postprandial period, and exenatide administration is not suitable for patients with severe renal impairment (creatinine clearance <30 mL/min) or end-stage renal disease. However, exenatide dosage adjustments are not required when used concomitantly with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (lovastatin), digoxin, angiotensin-converting enzyme (ACE) inhibitors (lisinopril), or the anticoagulant warfarin.
**DPP-IV Inhibitors**

DPP-IV inhibitors suppress the degradation of a variety of bioactive peptides, including GLP-1, thereby extending their period of action.\(^5\) Vildagliptin (LAF237; Novartis Pharmaceuticals, Basel, Switzerland) and sitagliptin (MK-0431; Merck Pharmaceuticals, Whitehouse Station, NJ) are furthest along in late-stage clinical development among the DPP-IV inhibitors. Saxagliptin (BMS-477118; Bristol-Myers Squibb, Princeton, NJ) is also undergoing clinical testing; however, no clinical results have thus far been published.\(^5\)

**Vildagliptin**

In an exploratory 4-week dosing, phase 2 study in early stage T2DM patients, oral vildagliptin was associated with suppression of endogenous DPP-IV activity for \(~12\) hours and suppression of postprandial and fasting plasma glucose concentrations.\(^5\) In addition, basal and postprandial GLP-1 concentrations were increased compared with placebo-treated subjects. Basal and postprandial glucagon levels were reduced, but no change in plasma insulin concentrations was observed. There was no change in body weight during this short-term study. Nasopharyngitis and mild headache were the most common adverse events reported more frequently in the vildagliptin group. No hypoglycemia was observed, as expected for patients with diet-controlled diabetes.

Three 12-week vildagliptin clinical trials, with the third followed by an open-label extension to 1 year, have been reported.\(^5\) In one 12-week, randomized, placebo-controlled phase 2 study using vildagliptin in T2DM patients taking metformin, vildagliptin-treated subjects had an HbA1c reduction of \(-0.7 \pm 0.1\)% compared with placebo.\(^5\) Fasting and postprandial plasma glucose concentrations were reduced, but there was no change in plasma insulin concentrations. Vildagliptin was generally well tolerated with cough and nasopharyngitis, the most common adverse events. After 52 weeks of vildagliptin exposure in an extension study patients maintained HbA1c reduction, compared with an HbA1c increase in the placebo plus metformin group, yielding a between treatment arm difference of \(-1.1 \pm 0.2\)%. There was no difference in body weight between treatment arms. Based on fasting glucose and insulin concentrations, there was no change in insulin resistance. However, evaluation of meal test data from a subset of these patients showed a small reduction in postprandial glucose excursions paired with a small increase in postprandial insulin concentrations.\(^6\)

**Sitagliptin**

The results of 2 dose ranging, 12-week phase 2 clinical trials in T2DM patients given sitagliptin identified active doses and dosing regimens for further study.\(^6\) In the first study, sitagliptin doses ranging from 25 to 100 mg once daily or 50 mg twice daily were associated with reductions in HbA1c compared with placebo. One hypoglycemic event occurred in each sitagliptin group, and there was no change in body weight. In the second study, reductions in HbA1c were observed with 50 mg of sitagliptin twice daily in concert with no weight change, versus a 1.1 kg weight gain for T2DM patients treated with glipizide. Hypoglycemia occurred in both groups, but at a higher frequency in the glipizide group. Results of phase 3 trials have not, to date, been published. However, a New Drug Application (NDA) for sitagliptin is under review at the FDA (15 February 2006 Merck & Co, press release), and more recently, Novartis also filed an NDA for vildagliptin with the FDA (March 30, 2006 Novartis press release).

**β-Cell Function**

Halting, or even reversing, the deterioration of the pancreatic β-cell that accompanies disease progression is the ultimate goal of therapeutic intervention for T2DM. Preclinical data have suggested the possibility that incretin mimetics and DPP-IV inhibitors might have activity in this arena. However, further clinical data are needed to definitively address this issue.

**Exenatide As a Treatment Option for Patients with Type 2 Diabetes**

When considering the use of exenatide, several factors should be considered in addition to the topics discussed above:

1. Is your patient taking insulin or other antidiabetic agents, other than metformin or a sulfonylurea? Exenatide is not a substitute for insulin and discontinuing insulin abruptly to initiate exenatide may cause hyperglycemia. In addition, the risk of hypoglycemia for combination therapy with exenatide and insulin is unknown. Concurrent use of exenatide with
α-glucosidase inhibitors, meglitinides, or d-phenylalanine derivatives has not been studied. Clinical trial data for the combination of exenatide with thiazolidinediones are pending.

2. Is your patient taking a sulfonylurea? In 30-week clinical trials, the incidence of hypoglycemia was greater for the combination of exenatide and a sulfonylurea than for the combination of placebo and a sulfonylurea.

3. Inform your patients that they may experience nausea at the beginning of treatment. If significant nausea is experienced with the 10 μg twice daily dose of exenatide, patients can reduce their dose to 5 μg twice daily, and then attempt to return to 10 μg at a later time. In addition, anti-emetic agents or over-the-counter remedies may help patients with nausea. Varying administration time may also help, as long as exenatide is taken within 1 hour before eating. If nausea persists, exenatide discontinuation should be considered.

4. What other medications is your patient taking? Exenatide should be used with caution in patients taking oral medications that require rapid gastrointestinal absorption, due to its actions to slow gastric emptying. Patients should be advised to take these medications at least 1 hour before exenatide injection. If oral medications must be ingested with food, patients should take them with a meal or snack when exenatide is not dosed.

**Case Report 1**

RM is a 68-year-old Caucasian male retired from oil refinery work. His HbA1C was 8.9% on January 12, 2006 with a fasting blood glucose concentration of 153 mg/dL and postprandial glucose concentrations of 167 to 207 mg/dL. RM’s weight was 258 lbs on February 13, 2006 with a body mass index of 38.1 kg/m². He was being treated with metformin, Toprol XL (50 mg daily), HCTZ (25 mg daily), Norvasc (10 mg daily), and Pravachol (40 mg daily). RM was upgraded from a generic glucose meter to a contour, provided with an 1800 calorie meal plan for weight control, and registered for evening diabetes classes. RM needed to improve his glycemic control, focus on lifestyle interventions, and begin weight loss. After 3 weeks of evening classes focusing on exercise, nutrition, and medication information, RM was started on BYETTA® (5 μg twice daily) on February 21, 2006. RM was contacted by telephone the next day and reported no nausea and a postprandial glucose reading of 130 mg/dL after his first injection. In addition, he reported not feeling hungry all the time. On April 6, 2006, RM’s HbA1C was 7.4% and his weight was 252 lbs. By August 2006, RM’s HbA1C was 6.2% with a fasting blood glucose of 106 to 117 mg/dL, a postprandial glucose range of 78 to 110 mg/dL, and a body weight of 249 lbs. RM reported improved blood pressure and blood sugars, decreased appetite (not “munching” so much), and feeling better overall.

**Case Report 2**

John is a 72-year-old, obese male with treated sleep apnea and a 2-year history of type 2 diabetes. He has HbA1C of 7.4% and routinely checks his morning blood glucose and finds it to be 135 to 170 mg/dL. John has been on metformin XL (2000 mg/day) and lisinopril (40 mg/day), simvastatin (40 mg/day), acetylsalicylic acid (ASA), and atenolol (50 mg/day). He has a history of syndrome X and a 50% right carotid stenosis. He is 5’10” and weighs 225 lbs. John describes himself as always being hungry for as long as he can remember and has difficulty controlling his diet. Recently, his creatinine has been increasing to 1.3 mg/dL, and a concern was raised about continuing him on metformin. We discussed adding a thiazolidinedione, but because of intermittent edema, a decision was made to put him on exenatide. John was started on 5 μg of exenatide subcutaneously, twice daily after being instructed by nursing on injection and dosing procedures. In addition, John’s metformin dose was reduced to 1000 mg/day. Over the first week, John experienced some mild nausea but was able to stay on the new medication. He described increased satiety and control over his appetite. This effect started to wane by week 3, and at week 4 his exenatide dosage was increased to 10 μg twice daily. Initially, the patient once more reported some transient nausea and earlier satiety. At the time of increased dosage, John was instructed to stop his metformin because his glucose was routinely approximately 90 to 110 mg/dL during fasting. John lost 3 lbs the first month and 2 lbs the second month, and reported being less hungry; however, over time he had mixed feelings about his decreased enthusiasm for food. He was maintained on the exenatide and by the end of month 3, his
HbA1c was at 6.5% and he has continued a slow but steady weight loss of 1 lb monthly since then.

**Concluding Remarks**

Clinical trial data using treatment strategies for type 2 diabetes that take advantage of the glucoregulatory effects of incretin hormones suggest these agents will fill a new niche in diabetes management. The multiple mechanisms of action reported for these agents include enhancement of glucose-dependent insulin secretion, suppression of inappropriately elevated glucagon secretion, slowing of gastric emptying, inhibition of food intake, and possibly, improvement of the underlying disease state through reversal of body weight gain and possible halting of progressive loss of pancreatic function. The problem of weight gain with most currently available diabetes treatments, and the progressive worsening of the T2DM disease state as a consequence, has focused attention on weight modulation as an area of differentiation for future therapeutics. Eighty-two week clinical data for exenatide support progressive reductions in body weight with accompanying sustained improvements in glycemic control. Although incretin mimetics and DPP-IV inhibitors may offer unique benefits to T2DM patients when used as monotherapy or in combination with established therapies for insulin resistance (weight loss, exercise, thiazolidinediones), suppression of glucose production (metformin), and insulin supplementation (insulin, sulfonylureas), much of this has not been researched and reported in the literature.

**Note added in proof**

Sitagliptin was approved by the US Food and Drug Administration in October 2006 for the treatment of type 2 diabetes.

**References**


51. BYETTA® prescribing information. Available from: http://www.byetta.com/index.jsp?reqNavId=0. BYETTA® is a registered trademark of Amylin Pharmaceuticals, Inc, San Diego, CA.


